Bayanin Jagora Akan Lenvatinib Don Ciwon daji - AASraw
AASraw yana samar da NMN da NRC foda a cikin girma!

Lenvatinib

 

  1. Tarihin Lenvatinib
  2. Menene Lenvatinib?
  3. Tsarin Lenvatinib na aiki
  4. Me ake amfani da Lenvatinib?
  5. Waɗanne Illolin Side Zan Iya Sanarwa Lokacin da kuke Amfani da Lenvatinib?
  6. Sakamako na asibiti na Lenvatinib (Amincewa da FDA)
  7. A ina zan kiyaye Lenvatinib?
  8. Magunguna masu dangantaka: Lenvatinib Mesylate (CAS: 857890-39-2)
  9. A Ina Zamu Sayi Lenvatinib akan layi?

 

Tarihin Of Lenvatinib

An yi gwajin gwajin lokaci na farko a marasa lafiya a 2006. [8] Wani gwaji na lokaci na uku da ke kula da marasa lafiyar kansar thyroid ya fara ne a watan Maris na 2011.

An bai wa Lenvatinib matsayin marayu don maganin nau'o'in cututtukan thyroid wanda ba ya amsa rediyo a cikin Amurka da Japan a cikin 2012 da Turai a 2013.

A watan Fabrairun 2015, FDA ta Amurka ta amince da lenvatinib don maganin ci gaba, rashi na rediyo ya banbanta cutar kansa. A watan Mayu 2015, Hukumar Kula da Magunguna ta Turai (EMA) ta amince da maganin iri ɗaya.

A watan Mayu 2016, FDA ta amince da shi (a haɗe tare da everolimus) don maganin ciwan ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayarfancin da akekeka a cikin watan Mayu na XNUMX, tare da everolimus.

A watan Agusta 2018, FDA ta amince da lenvatinib don yin layin farko na mutanen da ke fama da cutar sankarar hanta (HCC).

 

Abin da ke Lenvatinib?

Lenvatinib (CAS:417716-92-8) shine mai karɓar mai karɓar tyrosine kinase (RTK) mai hanawa wanda ke hana ayyukan kinase na ƙananan ƙwayoyin cuta masu tasowa (VEGF) masu karɓar VEGFR1 (FLT1), VEGFR2 (KDR), da VEGFR3 (FLT4). Lenvatinib kuma ya hana wasu RTKs waɗanda ke da alaƙa da cutar angiogenesis, haɓakar tumo, da ci gaban ciwon daji ban da ayyukan salula na yau da kullun, gami da masu karɓar haɓakar fibroblast (FGF) masu karɓar FGFR1, 2, 3, da 4; platelet mai karɓar haɓakar haɓakar haɓakar alpha (PDGFRα), KIT, da RET. Wadannan masu karɓa na tyrosine kinases (RTKs) da ke cikin membrane suna taka muhimmiyar rawa wajen kunna hanyoyin canza sigina da ke cikin ƙa'idodi na yau da kullun game da salon salula, kamar haɓaka kwayar halitta, ƙaura, apoptosis da bambance-bambancen, kuma a cikin cututtukan angiogenesis, lymphogenesis, ci gaban tumo da ci gaban kansa. Musamman, VEGF an gano shi azaman mai mahimmanci mai mahimmanci na ilimin ilimin lissafi da ilimin cututtuka da haɓaka maganganu na VEGF yana haɗuwa da mummunan hangen nesa a yawancin nau'ikan cutar kansa.

Ana nuna Lenvatinib don kula da marasa lafiya tare da maimaitawa na gida ko na asali, ci gaba, iodine na rediyo (RAI) - ɓarkewa daban-daban na maganin cutar kansa. Yawancin marasa lafiya da ke fama da cutar kansa suna da kyakkyawan hangen nesa tare da magani (ƙimar rayuwa na 98% na shekara 5) wanda ya shafi tiyata da maganin hormone. Koyaya, ga marasa lafiya tare da RAI-ƙyamar cutar ta thyroid, zaɓuɓɓukan magani sun iyakance kuma rashin lafiyar ba shi da kyau, wanda ke haifar da turawa don ci gaba da ƙarin hanyoyin kwantar da hankali kamar lenvatinib.

 

Lenvatinib Tsarin aikin

Lenvatinib mai karɓar maganin tyrosine kinase ne (RTK) mai hanawa hakan yana hana ayyukan kinase na masu karɓa na jijiyoyin jijiyoyin jiki (VEGF) masu karɓar VEGFR1 (FLT1), VEGFR2 (KDR), da VEGFR3 (FLT4). Lenvatinib kuma ya hana wasu RTKs waɗanda ke da alaƙa da cutar angiogenesis, haɓakar tumo, da ci gaban ciwon daji ban da ayyukan salula na yau da kullun, gami da masu karɓar haɓakar fibroblast (FGF) masu karɓar FGFR1, 2, 3, da 4; platelet mai karɓar haɓakar haɓakar haɓakar alpha (PDGFRα), KIT, da RET.

AASraw ƙwararren masani ne na Lenvatinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

Abin da ke Lenvatinib Amfani Don? 

❶ Lenvatinib ana amfani dashi don magance wani nau'in thyroid ciwon daji wanda ya dawo ko kuma ya bazu zuwa wasu sassan jiki kuma ba za a iya magance shi da iodine na rediyo.

Is Ana amfani da Lenvatinib tare da everolimus (Afinitor, Zortress) don magance ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (RCC, wani nau'in ciwon daji wanda ke farawa a cikin koda) a cikin mutanen da suka taɓa karɓar magani tare da wani magani na chemotherapy.

Also Lenvatinib kuma ana amfani dashi don magani carcinoma hepatocellular (HCC; wani nau'in ciwon hanta) wanda ba za a iya magance shi ta hanyar tiyata ba.

Also Ana amfani da Lenvatinib tare da pembrolizumab (Keytruda) don magance wani nau'in ciwon daji na endometrium (rufin mahaifa) wanda ya bazu zuwa wasu sassan jiki ko ya ta'azzara a yayin ko bayan jiyya tare da magungunan cutar sankara ko kuma wanda ba za a iya magance shi ta hanyar tiyata ba ko kuma ta hanyar fitila.

En Lenvatinib yana cikin rukunin magunguna da ake kira kinase inhibitors. Yana aiki ta hanyar toshe aikin wani furotin mara kyau wanda ke nuna ƙwayoyin kansar su ninka. Wannan yana taimakawa dakatar da yaduwar kwayoyin cutar kansa.

 

Abin da Sa nan Eilla May Ina Notice Wto Kuna Amfani Lenvatinib?

Hanyoyin lalacewa waɗanda ya kamata ku ba da rahoto ga likitanku ko ƙwararrun masu kiwon lafiya da wuri-wuri:

Reactions rashin lafiyan abubuwa kamar kumburin fata, ƙaiƙayi ko kumburi, kumburin fuska, leɓɓa, ko harshe

Matsalolin numfashi

Pain ciwon kirji ko bugun zuciya

Jiri

Jin suma ko saukin kai, faduwa

▪ ciwon kai

Hawan jini

Kamuwa

▪ alamomi da alamun jini kamar na jini ko na baki, kujerun tarry; fitsari ja ko duhu-ruwan kasa; tofa albarkacin jini ko launin ruwan kasa wanda yake kama da filin kofi; launin ja a fata; rauni ko jini daga ido, gumis, ko hanci

▪ alamomi da alamomin canji mai hadari a bugun zuciya ko kuma bugun zuciya kamar ciwon kirji; jiri; sauri ko bugun zuciya mara tsari bugun zuciya jin suma ko saukin kai, faduwa; matsalolin numfashi

▪ alamomi da alamomin raunin koda kamar matsalar matsalar fitsarin wucewa ko canzawar fitsarin

▪ alamomi da alamomin rauni na hanta kamar fitsari mai duhu ko ruwan kasa; rashin lafiyar gaba ɗaya ko alamun kamuwa da mura; kujerun launuka masu haske; asarar ci; tashin zuciya dama ciwon ciki na sama; rauni mara ƙarfi ko gaji; raunin idanu ko fata

▪ alamomi da alamomin low potassium kamar ciwon mara ko ciwon jiki; ciwon kirji; jiri; jin suma ko saukin kai, faduwa; bugun zuciya matsalolin numfashi; ko azumi, bugun zuciya mara tsari

▪ alamu da alamun bugun jini kamar canje-canje a cikin gani; rikicewa; matsala magana ko fahimta; tsananin ciwon kai; saurin suma ko rauni na fuska, hannu ko kafa; matsala tafiya; jiri; asarar daidaituwa ko daidaituwa

Pain ciwon ciki

▪ kumburin kafafu ko sawu

Weak rauni mara ƙarfi ko gaji

 

Hanyoyi masu illa waɗanda yawanci basa buƙatar likita (rahoto ga likitanka ko ƙwararrun likitocin kiwon lafiya idan sun ci gaba ko damuwa):

▪ gudawa

▪ ciwon mara

▪ rashin cin abinci

▪ ciwon baki

▪ ciwon tsoka

Use tashin zuciya, amai

Loss rashin nauyi

Wannan jerin bazai bayyana duk illolin da zasu iya haifarwa ba. Kira likitan ku don shawara na likita game da sakamako masu illa. Kuna iya bayar da rahoton sakamako masu illa ga FDA a 1-800-FDA-1088.

 

Lenvatinib

 

Lenvatinib Abubuwan Bincike(Amincewa da FDA)

The FDA ta yarda na Lenvatinib ya ta'allaka ne akan mahada da yawa, bazuwar, makafi biyu, gwajin sarrafa wuribo a cikin batutuwa 392 tare da maimaituwar gida ko metastatic radioactive iodine-refractory bambanta thyroid ciwon daji da kuma shaidar rediyo na ci gaba da cutar a cikin watanni 12 kafin bazuwar, an tabbatar da shi ta hanyar nazarin rediyo mai zaman kansa. Batutuwa sun karɓi Lenvatinib 24 MG sau ɗaya a rana (n = 261) ko placebo (n = 131) har sai ci gaban cuta. Sakamakon binciken ya nuna batutuwa da aka yiwa Lenvatinib sun rayu na tsaka-tsakin watanni 18.3 ba tare da cutar ta ci gaba ba (ci gaba ba tare da ci gaba ba), idan aka kwatanta da tsakani na watanni 3.6 don batutuwan da suka sami placebo. Bugu da ƙari, 65% na batutuwa da aka bi da su tare da Lenvatinib sun ga raguwar girman ƙari, idan aka kwatanta da 2% na batutuwa waɗanda suka karɓi placebo.

AASraw ƙwararren masani ne na Lenvatinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

A ina zan kiyaye Lenvatinib?

Ka daina samun damar yara.

Adana tsakanin 20 da 25 digiri C (68 da 77 digiri F). Yi watsi da duk wani magani da ba a amfani da shi bayan ranar karewa.

NOTE: Wannan takardar takaitaccen bayani ne. Maiyuwa bazai rufe duk wasu bayanai ba. Idan kana da tambayoyi game da wannan maganin, yi magana da likitanka, likitan magunguna, ko mai ba da kiwon lafiya.

 

Magunguna masu dangantaka: Lenvatinib Mesylate (CAS: 857890-39-2)

Lenvatinib mesylate (CAS: 857890-39-2) na roba ne, mai ba da maganin a fili na mai karɓar haɓakar haɓakar haɓakar ƙwayar cuta 2 (VEGFR2, wanda aka fi sani da KDR / FLK-1) tyrosine kinase tare da yiwuwar aikin antineoplastic. E7080 ya toshe VEGFR2 kunnawa ta VEGF, wanda ya haifar da hana hanyar karɓar siginar siginar mai karɓar VEGF, rage ƙaura da ƙwayoyin kwayar cutar ta endothelial, da kuma apoptosis cell endothelial cell.

Lenvatinib mesylate shine gishirin methanesulfonate wanda aka samu ta hanyar aikin lenvatinib tare da molar daya yayi daidai da methanesulfonic acid. Mai amfani da magunguna da marayu da aka yi amfani da shi (azaman gishirin mesylate) don maganin nau'o'in cututtukan thyroid wanda ba ya amsa rediyon. Tana da rawa a matsayinta na mai hana EC 2.7.10.1 (mai karɓar protein-tyrosine kinase) mai hanawa, haɓakar haɓakar haɓakar haɓakar fibroblast, mai ba da magani marayu, mai karɓar maganin ƙarancin jijiyoyin jijiyoyin ciki da wakilin antineoplastic. Ya ƙunshi lenvatinib (1+).

 

Lenvatinib mesylate an yarda da amfani dashi shi kaɗai ko tare da wasu magunguna don bi da:

Ndom Ciwon daji na ƙarshe wanda ya ci gaba kuma ya daɗa lalacewa bayan wasu hanyoyin kwantar da hankali. Ana amfani da shi tare da pembrolizumab a cikin marasa lafiya wanda cutar kansa ba microsatellite rashin ƙarfi ba ne-mai ƙarfi (MSI-H) ko rashin daidaitaccen gyara (dMMR) kuma ba za a iya bi da shi ta hanyar tiyata ko kuma fitilar radiation ba.

Cin Hepatocellular carcinoma (wani nau'in ciwon hanta). Ana amfani dashi azaman magani na farko a marasa lafiya wanda ba za'a iya kawar da cutar ta hanyar tiyata ba.

Ciwon ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (irin na ciwon koda) wanda ya ci gaba. Ana amfani dashi tare da everolimus a cikin marasa lafiya waɗanda suka riga sun karɓi maganin mai hana angiogenesis.

Cancer Ciwon daji na thyroid a cikin wasu marasa lafiya tare da ci gaba, maimaitawa, ko cuta mai haɗari wanda ba ya amsa magani tare da iodine na rediyo.

An yarda da wannan amfani a ƙarƙashin Shirin Inganta roaddamarwa na FDA. A matsayin sharaɗin yarda, gwajin tabbatarwa dole ne ya nuna cewa lenvatinib mesylate yana ba da fa'idar asibiti a cikin waɗannan marasa lafiya. Ana kuma nazarin Lenvatinib mesylate wajen maganin wasu nau'ikan cutar kansa.

 

A Ina Zamu Sayi Lenvatinib online?

Akwai masu kawowa / masana'antun lenvatinib foda a kasuwa, gano na gaske yana da mahimmanci ga duk mutanen da ke buƙatar wannan samfurin cikin gaggawa. Lokacin da muka yanke shawarar siyan lenvatinib foda a kasuwa, muna buƙatar ƙarin koyo game da shi, ku san yadda ake amfani da shi kuma tsarin aiki ne, kowane haɗari idan muka ɗauki lenvatinib foda…. Bugu da kari, farashi da inganci dole ne damuwar mu kafin mu siya.

Bayan mun bincika bayanan daga kasuwa, idan aka kwatanta yawancin masu samarwa, AASraw ya zama kyakkyawan zaɓi ga waɗanda suke son siyan yawancin abubuwa lenvatinib foda, ana sarrafa sarrafa su sosai a cikin yanayin cGMP, ana iya sa ido kan ingancin kowane lokaci kuma suna iya samar da duk rahotannin gwaji lokacin da kuke yin oda. Amma farashin lenvatinib foda / farashi, yakamata yayi daidai, a idanuna. Saboda na sami farashi da yawa daga masu kawowa daban-daban, idan aka kwatanta da inganci, ina tsammanin aasraw ba zai zama mummunan zaɓi ba.
Don ƙarin cikakkun bayanai, maraba don magana da AASraw!

 

reference

[1] H. Erdem, C. Gündogdu, da S. Üipal, "Daidaitawar E-cadherin, VEGF, maganganun COX-2 zuwa sigogin hangen nesa a cikin kwayar cutar sankarau ta kashin jini," Gwajin gwaji da Kwayoyin Halitta, vol. 90, babu. 3, shafi na 312-317, 2011.

[2] M. Yagi, S. Kato, Y. Kobayashi et al., "Zaɓin hanawa na karɓar karɓaɓɓen ƙwayar ƙarfe (PDGF) mai karɓar autophosphorylation da kuma abubuwan PDGF masu sassauƙan layin salula ta hanyar kwatancin quinoline," Binciken Gwajin Cell, vol. 234, a'a. 2, shafi na 285-292, 1997.

[3] P. Soares, J. Lima, A. Preto et al., "Canje-canjen halittu a cikin ƙananan ƙwayoyin maganin karoid," Yanzu. Genomics, kundi 12, babu. 8, shafi na 609-617, 2011.

[4] MM Moura, BM Cavaco, V. Leite. RAS proto-oncogene a cikin medullary thyroid carcinoma. Endocr Relat Cancer, 22 (5) (2015), shafi na R235-R252.

[5] BR Haugen, SI Sherman Sauye-sauye masu zuwa ga marasa lafiya da ke da bambancin bambancin cutar kansa. Endocr Rev, 34 (3) (2013), shafi na 439-455.

[6] M. Xing, D. Clark, H. Guan, da sauransu. BRAF maye gurbi na maganin ƙarancin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta. J Jarar Oncol, 27 (18) (2009), shafi na 2977-2982.

[7] SR Wedge, DJ Ogilvie, M. Dukes, et al. ZD6474 yana hana siginar haɓakar ƙarancin jijiyoyin jijiyoyin jijiyoyin jini, angiogenesis, da ci gaban tumo bayan bin baka. Ciwon Cancer, 62 (16) (2002), shafi na 4645-4655.

[8] SI Sherman, EEW Cohen, P. Schoffski, et al. Inganci na cabozantinib (Cabo) a cikin medullary thyroid cancer (MTC) marasa lafiya tare da maye gurbin RAS ko RET: Sakamako daga binciken lokaci na III [m]. J Jarar Oncol, 31 (15 Suppl.) (2013) abstr 6000.

[9] SI Sherman, LJ Wirth, JP Droz, et al. Motesanib diphosphate a cikin ci gaba daban-daban bambancin cututtukan thyroid. N Engl J Med, 359 (1) (2008), shafi na 31-42.

[10] K. Okamoto, K. Kodama, K. Takase, et al. Ayyukan antitumor na maƙasudin multi-tyrosine kinase inhibitor lenvatinib (E7080) a kan RET gene fusion-kore tumor model. Cancer Lett, 340 (1) (2013), shafi na 97-103.

[11] E. Cabanillas, M. Schlumberger, B. Jarzab, et al. Wani gwaji na zamani na 2 na lenvatinib (E7080) a cikin ci gaba, ci gaba, rediyo-mai ƙin yarda, bambancin cutar kanjamau: sakamakon asibiti da ƙididdigar masanin kansar, 121 (16) ( 2015), shafi na 2749-2756.

0 Likes
219 Views

Za ka iya kuma son

Comments an rufe.